Evidence map›Paper›PMID 23869245›Full record

ArticlePloS one2013

Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail.

Zachary F Zimmerman, Rima M Kulikauskas, Karol Bomsztyk, Randall T Moon, Andy J Chien

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 74 citations in OpenAlex.

  1. A Model of Butyrate Activity and Resistance in CRC.Journal of cellular and molecular medicine · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. NUMB as a Therapeutic Target for Melanoma.The Journal of investigative dermatology · 2022
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Neddylation is critical to cortical development by regulating Wnt/β-catenin signaling.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zachary F ZimmermanDepartment of Medicine, the University of Washington School of Medicine, Seattle, Washington, USA.
Rima M Kulikauskas
Karol Bomsztyk
Randall T Moon
Andy J Chien
University of Washington · US

Funding

TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
LAMININ GENE EXPRESSION IN GLOMERULAR CELLSR37DK045978 · NIDDK · UNIVERSITY OF WASHINGTON · PI BOMSZTYK, KAROL · 2003 to 2011
$2.2M
Acute Renal Failure: An Endotoxin Hyper-Responsive StateR01DK083310 · NIDDK · UNIVERSITY OF WASHINGTON · PI BOMSZTYK, KAROL, ZAGER, RICHARD A. · 2010 to 2013
$1.5M
Howard Hughes Medical InstituteNCI NIH HHS T32 CA009515NCI NIH HHS T32-CA009515NHLBI NIH HHS T32 HL007093NIDDK NIH HHS R01 DK083310NIDDK NIH HHS R01-DK083310NIDDK NIH HHS R37 DK045978NIDDK NIH HHS R37-DK45978
6 · The paper itself

Abstract

While the TRAIL pathway represents a promising therapeutic target in melanoma, resistance to TRAIL-mediated apoptosis remains a barrier to its successful adoption. Since the Wnt/β-catenin pathway has been implicated in facilitating melanoma cell apoptosis, we investigated the effect of Wnt/β-catenin signaling on regulating the responses of melanoma cells to TRAIL. Co-treatment of melanoma cell lines with WNT3A-conditioned media and recombinant TRAIL significantly enhanced apoptosis compared to treatment with TRAIL alone. This apoptosis correlates with increased abundance of the pro-apoptotic proteins BCL2L11 and BBC3, and with decreased abundance of the anti-apoptotic regulator Mcl1. We then confirmed the involvement of the Wnt/β-catenin signaling pathway by demonstrating that siRNA-mediated knockdown of an intracellular β-catenin antagonist, AXIN1, or treating cells with an inhibitor of GSK-3 also enhanced melanoma cell sensitivity to TRAIL. These studies describe a novel regulation of TRAIL sensitivity in melanoma by Wnt/β-catenin signaling, and suggest that strategies to enhance Wnt/β-catenin signaling in combination with TRAIL agonists warrant further investigation.

Indexed as

ApoptosisWnt Signaling PathwayApoptosis Regulatory ProteinsAxin ProteinBcl-2-Like Protein 11beta CateninCell Culture TechniquesCell Line, TumorCulture Media, ConditionedGlycogen Synthase Kinase 3HumansMelanomaMembrane ProteinsMyeloid Cell Leukemia Sequence 1 ProteinProtein Kinase InhibitorsProto-Oncogene ProteinsApoptosis Regulatory ProteinsAXIN1 protein, humanAxin ProteinBBC3 protein, humanBCL2L11 protein, humanBcl-2-Like Protein 11beta CateninCulture Media, ConditionedGlycogen Synthase Kinase 3MCL1 protein, humanMembrane ProteinsMyeloid Cell Leukemia Sequence 1 ProteinProtein Kinase InhibitorsProto-Oncogene ProteinsTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanWnt3A ProteinWNT3A protein, human

Identifiers

PMID23869245
PMCPMC3711908
OpenAlexW2082332913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.